Vancouver, B.C., January 14, 2020 – Solarvest BioEnergy Inc. (“Solarvest”, or the “Company”) (TSXV:SVS) announces that further to its news release dated January 6, 2021, it has received the TSX Venture Exchange Final Approval for the Shares for Debt Transaction whereby 525,000 Common Shares of the Company were issued in order to settle a debt of $73,500.
All Common Shares issued in connection with the Transaction are subject to resale restrictions for a period of four months and one day under applicable securities legislation.
Solarvest BioEnergy Inc. is a biologics company whose algae production platform provides it with an extremely flexible system capable of producing numerous products ranging from Omega 3 fatty acids to human therapeutic proteins. The company has produced the world’s first organic high DHA Omega-3 for the global supplement market and is launching its first finished product in the USA on Amazon and its e-commerce site. These developed finished products will be offered to key retailers as house brands which will supply them a patented competitive advantage. The company has also successfully demonstrated the expression of a high value therapeutic protein, viral antigens (immune stimulating proteins), and Cecropins (antimicrobial peptide/protein). The company has initiated a program for the expression of CBD and THC to be produced in GMP fermentation facilities.
For further information contact:
Gerri Greenham, Chief Executive Officer
The TSX Venture Exchange has neither approved nor disapproved the contents of this news release.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Statements made in this news release may contain forward-looking statements that may involve a number of risks and uncertainties. Actual events or results could differ materially from the Company’s expectations and projections.